Disease progression criteria | Univariate analysis | Multivariate analysis | Schoenfeld residuals | ||
---|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | p-value | |
aLenghth of the specific PFI | |||||
Age | 1.01 (0.99–1.03) | 0.27 | – | – | – |
Gender (m/f) | 1.13 (0.75–1.70) | 0.56 | – | – | – |
Tumor grade (G1 vs. G2) | 0.63 (0.33–1.20) | 0.16 | 0.99 (0.51–1.90) | 0.97 | 0.24 |
Tumor grade (G3/G4 vs. G2) | 1.57 (1.01–2.45) | 0.05* | 1.34 (0.85–2.12) | 0.20 | |
Tumor stage (stage I vs. stage II) | 0.32 (0.14–0.74) | 0.01* | 0.37 (0.15–0.89) | 0.03* | 0.05 |
Tumor stage (stage III/ IV vs. stage II) | 0.99 (0.46–2.16) | 0.98 | 1.09 (0.50–2.39) | 0.83 | |
IFNL3 rs28416813 genotype (CG/GG vs. CC) | 0.60 (0.40–0.91) | 0.02* | 0.61 (0.40–0.93) | 0.02* | 0.60 |
aOS time | |||||
Age | 1.03 (1.01–1.05) | 0.01* | 1.01 (1.00–1.04) | 0.13 | 0.67 |
Gender (m/f) | 1.26 (0.83–1.93) | 0.28 | – | – | – |
Tumor grade (G1 vs. G2) | 0.76 (0.24–1.00) | 0.05* | 0.76 (0.36–1.60) | 0.47 | 0.24 |
Tumor grade (G3/G4 vs. G2) | 1.35 (0.85–2.13) | 0.20 | 1.13 (0.70–1.81) | 0.61 | |
Tumor stage (stage I vs. stage II) | 0.37 (0.16–0.86) | 0.02* | 0.40 (0.16–1.04) | 0.06(*) | 0.01 |
Tumor stage (stage III/ IV vs. stage II) | 0.90 (0.36–2.23) | 0.82 | 0.95 (0.38–2.40) | 0.92 | |
IFNL3 rs28416813 genotype (CG/GG vs. CC) | 0.66 (0.43–1.00) | 0.05* | 0.68 (0.44–1.07) | 0.09(*) | 0.66 |